Literature DB >> 21109410

Adaptive 18fluoro-2-deoxyglucose positron emission tomography/computed tomography-based target volume delineation in radiotherapy planning of head and neck cancer.

R N Moule1, I Kayani, T Prior, C Lemon, K Goodchild, B Sanghera, W L Wong, M I Saunders.   

Abstract

AIMS: This study investigated an adaptive threshold-based method to delineate the target volume using (18)fluoro-2-deoxyglucose ((18)FDG) positron emission tomography/computed tomography (PET/CT) before and during a course of radical radiotherapy or chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck.
MATERIALS AND METHODS: Ten patients were enrolled between March 2006 and May 2008. (18)FDG PET/CT scans were carried out 72h before the start of radiotherapy and then at three time points during radiotherapy (8-18, 36-50 and 66Gy). Functional volumes were delineated using an adaptive iterative algorithm weighted according to the mean standard uptake value (SUV(mean)) within the region of interest. The background (18)FDG uptake, maximum standard uptake value (SUV(max)) and SUV(mean) within the volumes were assessed.
RESULTS: There was no significant reduction in the primary target volumes defined by the adaptive threshold during radiotherapy. However, the SUV(max) significantly reduced within the primary (P=0.003-0.011) and lymph node (P<0.0001) target volume at 36-50 and 36-66Gy compared with 0Gy. The SUV(mean) was negatively correlated to radiation dose (P<0.0001-0.014). The ratio between the background uptake of (18)FDG and the SUV(mean) significantly reduced for both the lymph node target volume at 36-50Gy and the primary volume at 66Gy. The lack of significant correlation between the defined volume and radiation dose was because the SUV(mean) within the region of interest used to define the edge of the volume was equal to or less than the background (18)FDG uptake and the software was unable to effectively differentiate between tumour and background uptake.
CONCLUSIONS: The adaptive threshold method may be of benefit when used to define the target volume before the start of radiotherapy. This method was not beneficial during radiotherapy because the software is not sensitive enough to distinguish tumour from background and define a volume. (18)FDG PET/CT-guided volumes delineated by automatic adaptive thresholding methods should only be used for dose escalation with the pretreatment imaging.
Copyright © 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21109410     DOI: 10.1016/j.clon.2010.11.001

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  9 in total

1.  PET/CT in Radiotherapy Planning for Head and Neck Cancer.

Authors:  Katie Newbold; Ceri Powell
Journal:  Front Oncol       Date:  2012-12-10       Impact factor: 6.244

2.  Alterations in anatomic and functional imaging parameters with repeated FDG PET-CT and MRI during radiotherapy for head and neck cancer: a pilot study.

Authors:  Manil Subesinghe; Andrew F Scarsbrook; Steven Sourbron; Daniel J Wilson; Garry McDermott; Richard Speight; Neil Roberts; Brendan Carey; Roan Forrester; Sandeep Vijaya Gopal; Jonathan R Sykes; Robin J D Prestwich
Journal:  BMC Cancer       Date:  2015-03-17       Impact factor: 4.430

3.  Study of diffusion weighted MRI as a predictive biomarker of response during radiotherapy for high and intermediate risk squamous cell cancer of the oropharynx: The MeRInO study.

Authors:  C Paterson; S Allwood-Spiers; I McCrea; J Foster; M McJury; M Thomson; M Sankaralingam; D Grose; A James; M Rizwanullah; P McLoone; A Chalmers; A Duffton
Journal:  Clin Transl Radiat Oncol       Date:  2017-01-10

4.  Effect of different segmentation algorithms on metabolic tumor volume measured on 18F-FDG PET/CT of cervical primary squamous cell carcinoma.

Authors:  Weina Xu; Shupeng Yu; Ying Ma; Changping Liu; Jun Xin
Journal:  Nucl Med Commun       Date:  2017-03       Impact factor: 1.690

5.  Quantitative 18F-FDG PET analysis in survival rate prediction of patients with non-small cell lung cancer.

Authors:  Wenchao Ma; Minshu Wang; Xiaofeng Li; Hui Huang; Yanjia Zhu; Xiuyu Song; Dong Dai; Wengui Xu
Journal:  Oncol Lett       Date:  2018-07-18       Impact factor: 2.967

6.  Prognostic value of metabolic variables of [18F]FDG PET/CT in surgically resected stage I lung adenocarcinoma.

Authors:  Xiao-Yi Wang; Yan-Feng Zhao; Ying Liu; Yi-Kun Yang; Ning Wu
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

7.  Comparison of different automated lesion delineation methods for metabolic tumor volume of 18F-FDG PET/CT in patients with stage I lung adenocarcinoma.

Authors:  Xiao-Yi Wang; Yan-Feng Zhao; Ying Liu; Yi-Kun Yang; Zheng Zhu; Ning Wu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

8.  Weekly response assessment of involved lymph nodes to radiotherapy using diffusion-weighted MRI in oropharynx squamous cell carcinoma.

Authors:  Neelam Tyagi; Nadeem Riaz; Margie Hunt; Kenneth Wengler; Vaios Hatzoglou; Robert Young; James Mechalakos; Nancy Lee
Journal:  Med Phys       Date:  2016-01       Impact factor: 4.071

9.  Correlation analysis between metabolic tumor burden measured by positron emission tomography/computed tomography and the 2015 World Health Organization classification of lung adenocarcinoma, with a risk prediction model of tumor spread through air spaces.

Authors:  Xiao-Yi Wang; Yan-Feng Zhao; Lin Yang; Ying Liu; Yi-Kun Yang; Ning Wu
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.